Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

Osteoarthritis, Knee Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-controlled Cross-over, Exploratory Trial of Naproxen to Evaluate Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01557816
• Other study ID #: ALPMF-006-2010
• Status: Recruiting
• Phase: N/A
• First received: February 21, 2012
• Last updated: March 21, 2012
• Start date: December 2011
• Est. completion date: June 2012

Study information

• Verified date: February 2012
• Source: Analgesic Solutions
• Contact: Stephen Wright, M.D.
• Phone: 781-444-9605
• Email: swright[@]analgesicsolutions.com
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate various methods of measuring pain relief in subjects who have chronic OA of the knee. After a 1 week of wash-out from existing therapy, subjects will be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have another week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, or topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication.

Description:

This study aims to evaluate various methods of measuring pain relief in osteoarthritis (OA) of the knee. The duration of the study will be up to 5 weeks. Eligible subjects will have chronic OA of the knee. After meeting initial entry criteria and prior to randomization, there will be a 1 week wash-out from existing therapy. Subjects will then be treated in a blinded fashion for 1 week with either naproxen (3 days at 250 mg twice a day followed by 4 days at 500 mg twice a day) or placebo. After the first week of treatment, subjects will have a week of wash-out followed by a second period of 1 week of the alternate treatment. Subjects will not be allowed to use oral non-steroidal anti-inflammatory drugs (NSAIDs) or other oral analgesics, nor will they be allowed to use topical medications on their target knees during the study. Acetaminophen will be allowed as a rescue medication (as needed up to 2 g/day)but subjects will be told not to take acetaminophen at least 12 hours before study visits. Seventy (70) subjects will be randomized to ensure that 60 subjects complete both treatment arms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Subject able to read, comprehend and sign written Informed Consent Form

2. Subject is 21 years old or older

3. If female, should be post-menopausal or has negative urine test

4. Subject has some degree of target joint pain for the last 3 months

5. Subject has to have 3 out of six:

( )Age > 50 ( )Morning stiffness < 30 minutes ( )Crepitus on active motion ( )Bony enlargement ( )No palpable warmth of synovium

6. Subject had an X-ray of the target knee showing evidence of OA within the past 3 years

7. Target joint does not contain any type of orthopedic and/or prosthetic device

8. Subject is ambulatory

9. Subject is in good general medical and psychological health, and is capable of completing study assessments and procedures.

Exclusion Criteria:

1. Subject had an x-ray of the target knee showing Kellgren-Lawrence grade 4

2. Subject has any pain syndrome that has the potential to confound the assessment of the target knee.

3. the subject has a documented history of an adverse reaction to NSAIDs or acetaminophen

4. Subject is pregnant or breast feeding

5. Subject has sitting systolic pressure > 180 mmHg or < 90mmHg, and/or a sitting diastolic pressure > 100 mmHg or < 50 mmHg at screening

6. Subject has mass body index (BMI) > 35 kg/m2.

7. Subject has a Hospital Anxiety and Depression Scale (HADS) score > 12 on either subscale or has an established history of major depressive disorder not controlled with medication

8. Subject has had an introduction of physiotherapy, acupuncture, or transcutaneous electrical nerve stimulation within 4 weeks before screening, or has no stable regimen of these modalities.

9. Subject has a clinically significant abnormalities in clinical chemistry, hematology, coagulation, or urinalysis.

10. Subject has a significant history or renal impairment

11. Subject has a positive urine drug screen for alcohol, illicit drugs or nonprescribed controlled substances

12. Subject has dermatological lesions of the target knee or ipsilateral elbow at the time of screening.

13. Subject is unable to discontinue all formulations of prior analgesics

14. Subject has received any investigational drug within 30 days prior to screening

15. Subject has a history of active peptic ulceration, gastrointestinal bleeding, esophageal, or gastric or duodenal ulcer within 3 months of screening

16. Subject has had a surgical intervention for any pain within 3 months of screening or plans for surgical intervention while in the study

17. Subject has a documented history of inflammatory arthritis, including rheumatoid arthritis.

18. Subject has received local corticosteroid injections, viscosupplementation, or arthrocentesis in the target joint within 3 months of screening

19. Subject has received oral or intramuscular corticosteroids within the past 30 days

20. Subject is involved in an ongoing or settled worker's compensation claim, disability, or litigation related to any pain problem

21. Subject had used opioids for pain more than 4 days in the week preceding screening

22. Subject has a history of alcohol or drug abuse/dependence/misuse within 2 years of screening

23. Subject has history of acute coronary syndrome, ischemic or hemorrhagic stroke, transient ischemic attack, or previous revascularization procedure to coronary or peripheral vasculature, or has a history of congestive heart failure within 5 years of screening

24. Subject has had axillary lymph nodes removed bilaterally

25. Subject has a disease-related or iatrogenic coagulopathy, or had been diagnosed with thrombocytopenia or a functional platelet disorder

26. The subject is currently on an aromatase inhibitor.

27. Subject has a history of any condition that, in the Investigator's opinion, precludes participation in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• Naproxen
Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
• Placebo
Placebo for seven days given BID during either of the 2 treatment periods.

Locations

Country	Name	City	State
United States	Analgesic Solutions	Natick	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Analgesic Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of naproxen vs. placebo	Efficacy of naproxen VS placebo will be analyzed by efficacy end-points of within-subject difference. Efficacy evaluations will include: In-clinic pain intensity NRS (24-hour recall); WOMAC: pain subscale, stiffness subscale, function subscale, and total scores; Daily actiwatch pain intensity; In-clinic pain intensity NRS for curent pain at rest and after exercise; Thermal pain matching at rest and after exercise; PGIC (Patient's Global Impression of Change); Subject treatment reference	5 weeks	No
Primary	Safety	Safety of Naproxen VS Placebo; Safety evaluations will include: Adverse events (AEs)and serious AEs (SAEs); Vital signs; Clinical Laboratories; Concomitant medications	5 weeks	Yes